Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label study of doxorubicin versus trabectedin + doxorubicin in first-line advanced soft tissue sarcoma
2008-008922-55Phase 2Terminated
- Sponsor
- Spanish Group for Research on Sarcoma
- Start
- Mar 2009
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in soft tissue sarcoma (STS) comparing Doxorubicin with Trabectedin + doxorubicin (2 arms). Primary endpoints: Progression-free survival and Objective response rate. Started Mar 2009; status: terminated.
02
Drugs
trabectedindoxorubicin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on 2008-008922-55.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008922-55.